BIONEXUS GENE LAB CORP (BGLC) Stock Price & Overview

NASDAQ:BGLC • US0906283066

Current stock price

2.24 USD
+0.01 (+0.45%)
Last:

The current stock price of BGLC is 2.24 USD. Today BGLC is up by 0.45%. In the past month the price increased by 10.34%. In the past year, price decreased by -36%.

BGLC Key Statistics

52-Week Range1.92 - 15.6
Current BGLC stock price positioned within its 52-week range.
1-Month Range2.03 - 2.73
Current BGLC stock price positioned within its 1-month range.
Market Cap
5.286M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.28
Dividend Yield
N/A

BGLC Stock Performance

Today
+0.45%
1 Week
-10.40%
1 Month
+10.34%
3 Months
-46.02%
Longer-term
6 Months -58.75%
1 Year -36.00%
2 Years -68.27%
3 Years N/A
5 Years N/A
10 Years N/A

BGLC Stock Chart

BIONEXUS GENE LAB CORP / BGLC Daily stock chart

BGLC Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BGLC. When comparing the yearly performance of all stocks, BGLC is a bad performer in the overall market: 92.16% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BGLC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BGLC. BGLC has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BGLC Earnings

Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

BGLC Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

BGLC Groups

Sector & Classification

Index Membership

BGLC Financial Highlights

Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -220.64% compared to the year before.


Income Statements
Revenue(TTM)9.47M
Net Income(TTM)-2.30M
Industry RankSector Rank
PM (TTM) N/A
ROA -30.14%
ROE -33.7%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%47.39%
Sales Q2Q%-3.29%
EPS 1Y (TTM)-220.64%
Revenue 1Y (TTM)2.21%

BGLC Ownership

Ownership
Inst Owners2.12%
Shares2.36M
Float1.50M
Ins Owners12.39%
Short Float %1.82%
Short Ratio1.12

BGLC Competitors/Peers

The largest stocks on the US markets in the "Trading Companies & Distributors" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
FAST FASTENAL CO36.5552.203B
GWW WW GRAINGER INC24.4150.873B
URI UNITED RENTALS INC15.8346.445B
FERG FERGUSON ENTERPRISES INC17.643.422B
WSO WATSCO INC28.8114.949B
WSO.B WATSCO INC -CL B27.9714.907B
QXO QXO INC49.9714.299B
WCC WESCO INTERNATIONAL INC16.0712.462B
AIT APPLIED INDUSTRIAL TECH INC21.799.536B
CNM CORE & MAIN INC-CLASS A15.69.396B
AL AIR LEASE CORP12.717.211B
GATX GATX CORP16.515.982B
SITE SITEONE LANDSCAPE SUPPLY INC29.525.771B

About BGLC

Company Profile

BGLC logo image BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.

Company Info

IPO: 2020-03-11

BIONEXUS GENE LAB CORP

10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi

KUALA LUMPUR WILAYAH PERSEKUTUAN MY

Employees: 30

BGLC Company Website

BGLC Investor Relations

Phone: 13072416898

BIONEXUS GENE LAB CORP / BGLC FAQ

What does BGLC do?

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.


Can you provide the latest stock price for BIONEXUS GENE LAB CORP?

The current stock price of BGLC is 2.24 USD. The price increased by 0.45% in the last trading session.


Does BIONEXUS GENE LAB CORP pay dividends?

BGLC does not pay a dividend.


How is the ChartMill rating for BIONEXUS GENE LAB CORP?

BGLC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of BIONEXUS GENE LAB CORP (BGLC)?

BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).


What is the market capitalization of BGLC stock?

BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 5.29M USD. This makes BGLC a Nano Cap stock.